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• l-arginine reduced the antinociceptive effects of emulsiﬁed sevoﬂurane.
• Emulsiﬁed sevoﬂurane reduced the Fos protein expression in the spinal cord.
• l-arginine attenuated the suppression of sevoﬂurane in Fos protein expression.
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Thepurposeof this studywas to investigate the contributionof spinal nitric oxide (NO) to the antinocicep-
tive effects of emulsiﬁed sevoﬂurane in rats. Formalin tests were used to assess the nociceptive response.
Immunohistochemistry was performed to determine the effects of emulsiﬁed sevoﬂurane on formalin-
induced changes of Fos-like immunoreactive (Fos-LI)-positive neurons in the spinal cord. We found that
emulsiﬁed sevoﬂurane administered intraperitoneally at a dosage of 2.5ml/kg did not impair motor
performance in rats, but it signiﬁcantly decreased the formalin-induced paw licking time. Furthermore,
Fos-LI-positive neurons were mainly found in the ipsilateral dorsal horn after the injection of forma-
lin. The administration of emulsiﬁed sevoﬂurane signiﬁcantly decreased Fos-LI-labeled neurons. Finally,
intrathecal l-arginine alone did not affect the basal pain threshold, but it signiﬁcantly decreased the
antinociceptive response of emulsiﬁed sevoﬂurane against formalin injection and the suppressive effects
of sevoﬂurane on formalin-induced Fos protein expression (P<0.05). These data suggest that spinal cord
NO is involved in the antinociception of sevoﬂurane in rats.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Sevoﬂurane iswidely used in the clinical setting as an inhalation
anesthetic.Manystudieshaveshownthat sevoﬂuranehasanalgesic
properties and that its analgesic properties are mediated by the
spinal cord [1,2]. However, the exact mechanisms and pathways of
its anesthetic action are not clearly understood.
Previous experiments have shown that noxious stimulation
increases the expression of the c-fos proto-oncogene in subpop-
ulations of spinal cord neurons [3,4]. Therefore, the Fos protein,
the product of the c-fos immediate early gene, has been used as a
marker of activation of nociceptive pathways [5]. There is evidence
that the activation of nitric oxide synthase (NOS) with a conse-
quent production of NO plays an important role in the central and
∗ Corresponding author. Tel.: +86 512 8083 8800; fax: +86 512 8083 8800.
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peripheral modulation of nociception and the expression of the Fos
protein [6,7].
Certainly, NO is involved in the action of volatile anesthesia.
However, its role is far from being understood [8–10]. Few studies
have been dedicated to understanding the effects of spinal cord NO
on the antinociceptive of sevoﬂurane.
Based on these observations, the goal of this study was to ascer-
tain the role that NO plays at the spinal level in the antinociceptive
effects of emulsiﬁed sevoﬂurane using l-arginine.
2. Materials and methods
2.1. Animal preparation
The experiments were performed on healthy Sprague–Dawley
ratsweighing250–300g fromtheXuzhouMedical ExperimentAni-
mal Center. All experimental protocolswere approvedby the Ethics
http://dx.doi.org/10.1016/j.neulet.2015.02.006
0304-3940/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Committee for the use of experimental animals of Xuzhou Medical
University.
2.2. Intrathecal catheter
Intrathecal catheterization was based on the procedure
described by Yaksh [11]. Animals were injected intraperitoneally
with sodium pentobarbital (40mg/kg), and every rat received an
incision over the cervical spine, and a small puncture was made
in the dura mater. PE-10 polyethylene tubing(OD 0.55mm, ID
0.30mm) was threaded 7.5 cm into the intrathecal space. This tub-
ing was then sutured in place, and the skin was sutured tight over
the tubing. Correct catheter placement was veriﬁed by injecting 2%
lidocaine 10l down the catheter after recovery fromgeneral anes-
thesia. The catheter was considered to be introduced intrathecally
if paralysis and dragging of the two legs were observed after the
injection. Experiments were started 6 days after the placement of
the intrathecal catheter. Rats with neurological disturbances and a
negative lidocaine test were excluded from the following experi-
ments [12]. Intrathecal (i.t.) drug administrationwas accomplished
manually using a microinjection syringe (OD 0.5mm) connected
to the intrathecal catheter over a 10 s period in a single injection
with a volume of 10l followed by a ﬂush of 10l normal saline
(NS) in awake rats. Intraperitoneal (i.p.) drug administration was
performed in a single volume of 0.01 L/kg.
2.3. Formalin test
Formalin-induced pain was produced based on a previously
reported method [13]. Brieﬂy, 20l of 10% formalin solution was
injected subcutaneously (s.c.) under the plantar surface of the left
hind paw. The time that animals spent licking the injected paw
was monitored during the early phase (phase I) and during the late
phase (phase II). Phase I was deﬁned as the period of time from the
beginning immediately after formalin injection to the next 5min.
Phase II was deﬁned as the time from the ﬁrst 5min immediately
after post-formalin injection to the last 50min. Phase II was pro-
posed to be caused by central sensitization. The phase I response of
the formalin test was caused by the direct stimulation of nocicep-
tors by formalin or tissue damage, while phase II was proposed to
be caused by subsequent inﬂammation after formalin injection [8].
2.4. Experimental design
First, we evaluated the effect of l-arginine on antinociception of
emulsiﬁed sevoﬂurane on formalin-induced pain. Sixty-four ani-
mals were randomly assigned to one of eight groups (n=8 per
group). Group NS (rats received i.t. and i.p. injections of NS 10min
before s.c. injection of formalin); group l-arginine 10g, 20g,
and 40g (rats received i.t. injection of 10g, 20g, and 40g
of l-arginine, respectively, 10min before s.c. injection of forma-
lin). Group Sev (rats received i.p. injection of 2.5mL/kg emulsiﬁed
sevoﬂurane 10min before s.c. injection of formalin). Group l-Arg
10g+Sev group 20g+Sev and group 40g+Sev (rats received
i.t. injection of 10g, 20g, and 40g of l-arginine 10min before
i.p. injection emulsiﬁed sevoﬂurane and 10min before s.c. injection
of formalin) (Fig. 1).
To further reveal the role of NO in the effects of emulsiﬁed
sevoﬂurane, we used the Fos protein as a marker of the activation
of nociceptive pathways. A total of 54 rats were randomly divided
into 9 groups (n=6): (1) rats in group NS underwent i.t. injection
of NS; (2) rats in group Sev underwent i.p. injection of 2.5ml/kg
emulsiﬁed sevoﬂurane; (3) rats in group F underwent s.c. injection
of formalin; (4) rats in group NSip + F underwent i.p. injection of NS
10min before s.c. injection of formalin; (5) rats in group NSit + F
underwent i.t. injection of NS and s.c. injection of formalin; (6)
rats in group Sev+ F underwent i.p. injection of 2.5ml/kg emul-
siﬁed sevoﬂurane10min before s.c. injection of formalin; (7) rats
in group l-Argit + F underwent i.t. injection of 20g l-Arg 10min
before s.c. injection of formalin; (8) rats in group NSit + Sev+ F
underwent i.t. injection of NS, i.p. injection of 2.5ml/kg emulsiﬁed
sevoﬂurane10minbefore s.c. injectionof formalin; (9) rats ingroup
l-Argit + Sevip + F underwent i.t. injection of l-Arg i.p. injection of
2.5ml/kg emulsiﬁed sevoﬂurane 10min before s.c. injection of for-
malin using the fos immunohistochemistry technique, and changes
in the Fos expression in the spinal cord were observed (Fig. 2).
2.5. Immunohistochemistry
Based on a previous report [14], one hour after formalin injec-
tion, ratswereanesthetizedwith sodiumpentobarbital (100mg/kg.
i.p.) and underwent sternotomy. They were then intracardially
perfused with 250ml saline followed by 400ml 4% ice-cold
paraformaldehyde in 0.1mol/L phosphate buffer (PB). The spinal
cord from L4 to L5 was removed, post-ﬁxed in 4% paraformalde-
hyde for3h, and subsequently allowed toequilibrate in30%sucrose
in PB overnight at 4 ◦C. Thirty-micrometer transverse serial sec-
tions were cut on a cryostat and stored in phosphate buffered
saline (PBS). Tissue sectionswereperformed for Fos protein expres-
sion. Tissue sections were washed and incubated in PBS containing
5% normal goat serum and 0.3% Triton X-100 at room tempera-
ture for 30min, followed by primary rabbit anti-c-Fos antibody
(Sigma, 1:600) at 4 ◦C for 48h. Then, the sections were incubated
in biotinylated goat anti-rabbit IgG (1:200) at 37 ◦C for 1h, then
in the avidin–biotin–peroxidase complex (1:100) at 37 ◦C for 2h.
Finally, the sections were reacted with diaminobenzidine (DAB)
for 5–10min and then rinsed in 0.01mol/L PBS to stop the reac-
tion,mountedontogelatin-coatedslides, airdried,dehydratedwith
70–100% alcohol, cleared with xylene and cover slipped for micro-
scopic observation.
NS (n=8) NS i.t. 10min NS i.p. 10min Formalin. s.c
L-Arg 10μg (n=8) L-Arg 10μg i.t 10min Formalin. s.c
L-Arg 20μg (n=8) L-Arg 20μg i.t 10min Formalin. s.c
L-Arg 40μg (n=8) L-Arg 40μg i.t 10min Formalin. s.c
Sev  (n=8) Sev i.p.. 10min Formalin. s.c
L-Arg 10μg +Sev (n=8) L-Arg 10μg i.t 10min Sev i.p. 10min Formalin. s.c
L-Arg 20μg+ Sev (n=8) L-Arg 20μg  i.t 10min Sev i.p. 10min Formalin. s.c
L-Arg 40μg +Sev (n=8) L-Arg 40μg  i.t 10min Sev i.p.. 10min Formalin. s.c
Fig. 1. Paw licking time (PLT).
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NS (n=6) NS i.t.
Sev  (n=6) Sev i.p
F (n=6) Formalin. s.c
NSip + F (n=6) NS i.p. 10min Formalin. s.c
NSit + F (n=6) NS i.t 10min Formalin. s.c
Sev + F (n=6) Sev i.p. 10min Formalin. s.c
L-Arg
 it+F (n=6) L-Arg 20μg  i.t 10min Formalin. s.c
NSit + Sev + F (n=6) NS  i.t 10min Sev i.p.. 10min Formalin. s.c
L-Arg
 it+ Sev +F (n=6) L-Arg 20μg  i.t 10min Sev i.p.. 10min Formalin. s.c
Fig. 2. Fos expression in the spinal cord in rats.
Table 1
Paw licking time (PLT) in each group(n=8,
−
X± S).
Group PLT (s)
0∼5 (min) 1∼50 (min)
NS 68 ± 15 192 ± 78
l-Arg 10g 76 ± 11 185 ± 24
l-Arg 20g 89 ± 18 189 ± 27
l-Arg 40g 78 ± 12 178 ± 30
Sev 37 ± 17* 60 ± 12*
l-Arg 10g+Sev 40 ± 16* 64 ± 18*
l-Arg 20g+Sev 51 ± 12# 129 ± 27#
l-Arg 40g+Sev 70 ± 16# 128 ± 29#
* P<0.05 compared with Group NS.
# P<0.05 compared with Group Sev.
2.6. Counting of positive neurons
To observe the distribution of positive neurons, the spinal cord
was divided into four regions: superﬁcial laminae (I–II laminae),
nucleus proprious (III–IV laminae), neck of the dorsal horn (V–VI
laminae) and ventral laminae (VII–X laminae). We selected 5 sec-
tions per rat to count the greatest number of positive neurons in the
ipsilateral spinal cord. All positive neurons were counted without
considering the intensity of the staining.
2.7. Statistical analysis
The data were presented as the means± SD and analyzed with
SPSS 11.0 statistical software (SPSS Inc., Chicago, IL, USA). A one-
way analysis of variance (ANOVA) and post hoc Tukey’s test were
used to analyze the differences. P-values less than 0.05 were con-
sidered statistically signiﬁcant (P<0.05).
3. Results
3.1. Effects of systemic emulsiﬁed sevoﬂurane (2.5ml/kg, ip),
intrathecal l-arginine or their combination in the formalin test
In NS-treated rats, the duration of paw licking across the early
phasewas (68±18)s and across the late phasewas (192±78)s. The
administrations of emulsiﬁed sevoﬂurane 10min prior to formalin
injection signiﬁcantly reduced formalin-induced licking behaviors
during phase I and phase II (P<0.05). l-arginine (10g, 20g,
40g) administered intrathecally alone exhibited no effects on the
duration of paw licking, comparedwith baseline values and control
(P>0.05). Pretreatment with 20g and 40g l-arginine, but not
10g, signiﬁcantly reduced the effects of emulsiﬁed sevoﬂurane
on formalin-induced licking behaviors (P<0.05) (Table 1).
3.2. Fos protein expression
There were few Fos-like immunoreactivity (Fos-LI) positive
neurons in the spinal cord in the NS group. Systemic emulsiﬁed
sevoﬂurane alone had no effects on the expression of Fos-LI-
positive neurons in the spinal cord compared with the NS group
(P>0.05). Formalin-induced Fos-LI positive neurons were mainly
located in the superﬁcial laminae (I–II laminae) and neck (V–VI
laminae) of the ipsilateral spinal cord (Fig. 3A). The injection of
emulsiﬁed sevoﬂurane 10min prior to formalin injection could sig-
niﬁcantly reduce the number of Fos-LI neurons (Fig. 3B), compared
with the NSit + F group (P<0.05) (Table 2).
Intrathecal treatment with 20g of l-arginine alone had no
signiﬁcant effect on Fos protein expression in the spinal cord but
obviously attenuated the suppression of sevoﬂurane on formalin-
induced spinal cord Fos protein expression (Fig. 3C, Table 2).
4. Discussion
Previous laboratory studies have demonstrated that the
intraperitoneal injection of inhalation anesthetics also leads to
antinociceptive effects inmice [2,10,12]. According to pharmacoki-
netics and our pilot experiments, we conﬁrmed that i.p. or s.c.
injection of sevoﬂurane can achieve the same analgesic effect as
inhalation.
In this experiment, the dosage of 2.5ml/kg of emulsiﬁed
sevoﬂurane was selected. Systemic administration of emulsiﬁed
sevoﬂuraneat thisdosagedidnot impairmotorperformance in rats,
but showed an obvious antinociceptive response against forma-
lin injection. Moreover, intrathecal injection of l-Arg in conscious
rats had no obvious effects on motor performance but signiﬁ-
cantly inhibited the antinociception of sevoﬂurane in the formalin
test. Therefore, these results indicated that the reduction in the
Table 2
Fos expression in the spinal cord in rats (n=6,
−
X± S).
Group Entire section Lam I–II Lam III–IV Lam V–VI sLam VII–X
NS 11 ± 3 6 ± 3 3.1 ± 1.2 1.5 ± 1.0 0 ± 0
Sev 11 ± 3 5 ± 4 4.3 ± 1.5 1.4 ± 1.1 0 ± 0
F 222 ± 18 120 ± 13 57 ± 6 36 ± 6 25 ± 4
NSip + F 220 ± 20 122 ± 12 40 ± 7 37 ± 10 32 ± 6
NSit + F 204 ± 25 85 ± 16 50 ± 12 45 ± 10 27 ± 7
Sev+ F 126 ± 18* 65 ± 8* 24 ± 4* 20 ± 4* 18 ± 3*
l-Arg it + F 200 ± 26 95 ± 14 36 ± 9 38 ± 8 31 ± 7
NSit + Sev+ F 100 ± 12* 46 ± 10* 22 ± 5 27 ± 6* 14 ± 3*
l-Argit + Sev+ F 145 ± 19*,# 70 ± 11*,# 44 ± 6# 19 ± 7* 12 ± 4*
* P<0.05 compared with the Group NSip + F.
# P<0.05 compared with the Group NSit + Sev+ F.
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Fig. 3. A: Fos expression induced by formalin stimulation in the spinal cord in rats (Group F). B: Pretreatment with intrathecal NS had no effects on the suppression of i.p.
sevoﬂurane on spinal Fos expression induced by formalin stimulation in rats (Group NSit + Sev+ F). C: Pretreatment with intrathecal l-Argit 20g obviously attenuated the
suppression of sevoﬂurane on formalin-induced spinal cord Fos protein expression (P<0.05) (Group l-Argit + Sev+ F) (original magniﬁcation: ×100).
formalin-induced paw licking response after sevoﬂurane injection
was a result of antinociception but not an impairment of motor
function.
Fos has only a low level of basal expression in the normal spinal
cord tissue [15]. Peripheral stimulation can activate the Fos expres-
sion in the spinal cord. To a certain extent, the numbers of FLI
neurons were directly associated with the stimulation intensity,
and this has been used extensively to evaluate the analgesic efﬁ-
cacy of medicines [16–18]. In agreement with behavioral studies,
intraperitoneal injection of sevoﬂurane caused a signiﬁcant reduc-
tion in the amount of Fos-LI induced by formalin injection in the
spinal cord, suggesting that sevoﬂurane produces antinociceptive
effects partly at the spinal level.
It is well accepted that NO is an important biological mes-
senger in the central nervous system, including in nociception
transmission [19]. Feng found that NOS expression in hippocam-
pal neuronswas signiﬁcantly decreased after sevoﬂurane exposure
[20]. So we speculated that the expression of NO was involved in
sevoﬂurane-induced antinociceptive effects. In our study, intrathe-
cal pretreatment with NO precursor l-arginine alone neither
affected the formalin-induced pain behavior nor spinal cord
Fos expression, but inhibited sevoﬂurane-induced antinociceptive
effects and its suppressive effects on Fos expression. This result
indicates that spinal cord NO is involved in the antinociception of
sevoﬂurane in rats.
The spinal cord is the ﬁrst relay site in the transmission of noci-
ceptive information from the periphery to the brain. Nociceptive
signals are transmitted from the periphery by primary afferent
ﬁbers into the dorsal horn of the spinal cord. l-Arg the NO precur-
sor, attenuated the reduction of sevoﬂurane in the amount of F-LI in
laminae I–IV in the spinal cord, suggesting that laminae I–IV were
related more closely with the antinociception of sevoﬂurane. Pre-
treatment of sevoﬂurane in our study did not completely inhibit
Fos expression, suggesting that sevoﬂurane at that dosage could
not completely suppress the nociceptive signal transmission at the
spinal level.
There are some limitations relevant to the interpretation of the
results of the present study. First, the number of rats in each group
was small. Second, there is no objective indicator to evaluate the
depth of anesthesia, so we could only judge and evaluate the depth
of anesthesia indirectly by the movement ability of the rats. Third,
although we observed and discussed the effect of different dosages
of l-arginine on the antinociceptive effects of sevoﬂurane, we did
not discuss the effects of the time of intrathecal injection of l-
arginine on the antinociceptive effects of sevoﬂurane. Fourth, the
results of this study can only indirectly speculate that spinal NO
may be involved in antinociceptive effects of sevoﬂurane on pain
induced by formalin in rats. Further studies are needed to ﬁnd the
direct evidence to seewhether sevoﬂurane has analgesic effects via
the spinal production of NO.
We found that intrathecal pretreatment with the NO precur-
sor l-arginine signiﬁcantly reduced the antinociceptive effects of
sevoﬂurane in the formalin test. Furthermore, the systemic injec-
tion of sevoﬂurane signiﬁcantly decreased the formalin-induced
increases in Fos-LI labeled neurons in the spinal cord, which could
be partly reversed by l-arginine. Based on these data,we concluded
that the inhibition of spinal NO production may contribute to the
antinociceptive effects of sevoﬂurane on formalin-induced pain in
rats.
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